Store

Home | Store | Cell Therapy and Gene Therapy Disease Markets, 2023-2029

Cell Therapy and Gene Therapy Disease Markets, 2023-2029

Publication Date: April 30, 2024

SKU: 24-015

Tags: CAR-T Cell Therapy, Cell and Gene Therapy, Life Science, Oncology and Cancer

Pages: 270

SKU: 24-015

Explore the future of medicine with our in-depth report on cell therapy, gene therapy, and RNA therapy markets. Cell therapy and gene therapy represent a frontier in modern medicine, promising revolutionary treatments by treating the underlying genetic causes of disease and by genetically controlling the body’s immune system. Recent years have seen an increase in new therapies and the pipeline indicates this trend will continue. A large range of therapeutic areas from oncology to cardiology have seen rapidly proliferating clinical trials.

Discover the latest advancements and market trends in cell therapy, gene therapy, and RNA therapy with Kalorama Information’s comprehensive report, Cell Therapy and Gene Therapy Markets (Markets by Disease Type), 2023-2029. Explore how these cutting-edge treatments are revolutionizing healthcare by targeting genetic causes of diseases and harnessing the body’s immune system.

 

Key Features:

  • Market estimates and forecasts from 2023-2029
  • Development pipeline analysis
  • Competitive landscape assessment
  • Detailed chapters on oncology, neurology, musculoskeletal disorders, dermatology, cardiology, and other therapeutic areas

 

Scope:

  • Covers cell therapies, gene therapies, and RNA therapies
  • Excludes RNA therapies for COVID-19 and mRNA vaccines
  • Does not focus on cord blood products

 

Forecast:

  • Dollar figures represent estimated global market for 2023 and expected market for 2029
  • Forecasts provided through 2029, based on manufacturers’ revenues

 

Table: Global Cell and Gene Therapy Market, by Product Segment ($ millions)

 Segment 2023 2024 2025 2026 2027 2028 2029 CAGR
Neurology $XX Million $XX Million $XX Million $XX Million $XX Million $XX Million $XX Million XX%
Oncology $XX Million $XX Million $XX Million $XX Million $XX Million $XX Million $XX Million XX%
Musculoskeletal $XX Million $XX Million $XX Million $XX Million $XX Million $XX Million $XX Million XX%
Dermatology $XX Million $XX Million $XX Million $XX Million $XX Million $XX Million $XX Million XX%
Cardio/non-oncology blood $XX Million $XX Million $XX Million $XX Million $XX Million $XX Million $XX Million XX%
Other $XX Million $XX Million $XX Million $XX Million $XX Million $XX Million $XX Million XX%
Total $XX Million $XX Million $XX Million $XX Million $XX Million $XX Million $XX Million XX%

Source: Kalorama Information

For further details and to purchase directly, please contact us.

Table of Contents

Chapter 1: Executive Summary

Overview

Scope and Methodology

Market Overview and Potential

  • Figure 1-1: Global Cell and Gene Therapy Market, by Product Segment (Cardio/Non-Oncology Blood, Dermatology, Musculoskeletal, Neurology, Oncology, Other), 2023-2029 ($ millions)
  • Table 1-1: Global Cell and Gene Therapy Market, by Product Segment (Cardio/Non-Oncology Blood, Dermatology, Musculoskeletal, Neurology, Oncology, Other), 2023-2029 ($ millions)

 

Chapter 2: Introduction to Cell and Gene Therapy

Introduction

  • Table 2-1: Total Numbers of Approved Cell, Gene, & RNA Therapies, by Type, Q4 2022-Q1 2024 (ending March 2024), Global (count, %)
  • Figure 2-1: Share of Total Global Numbers of Approved Cell, Gene, & RNA Therapies, by Type, March 2024 (%)

Cell Therapy

  • CAR T
  • Stem Cells
  • Adult Stem Cells
  • Human Embryonic Stem Cells
  • Table 2-2: Adult vs. Embryonic Stem Cells

Gene Therapy

  • Table 2-3: Somatic vs. Germ Line Gene Therapy

Viral Vector System and New Developments

  • Table 2-4: Selected Examples of Viruses in Gene Therapy
  • Figure 2-2: Estimated Viral Vector Use in Commercialized Cell and Gene Therapies, by Type, 2022 (%)

Non-viral Systems for Transporting Genes

Gene Editing

Cell and Gene Therapy: Characteristics

  • Table 2-5: Cell Therapy vs Gene Therapy

Staffing

Manufacturing Process for CAR-T

Leukapheresis

Activation

Transduction

Expansion

Cell and Gene Therapy Manufacturing Processes

  • Table 2-6: Manufacturing Process Time for Select Autologous Cell and Gene Therapies (current and discontinued therapies)
  • Figure 2-3: Manufacturing Process Time for Select Autologous Cell and Gene Therapies (current and discontinued therapies)

Cost

Reimbursement

Logistics

Mergers and Acquisitions

  • Table 2-7: Selected Company Mergers and Acquisitions in the Cell and Gene Therapy Market

Deals, Agreements, and Collaborations

Regulatory Developments

Fast Track

Orphan Drug

Breakthrough Therapy

Accelerated Approval

Priority Review

  • Table 2-8: Regulatory Actions and Guidelines for Cell and Gene Therapy, by Select Country

Individualized Gene Therapy Approval Process

Pipeline, Development Overview

Pipeline, Development Progress

  • Table 2-9: Global Cell, Gene, & RNA Therapy Clinical Trial Growth (pre-clinical I through phase III), Q4 2022-Q1 2024 ($ millions, %)
  • Figure 2-4: Global Cell, Gene, & RNA Therapy Development Progress (pre-clinical through phase III), as of March 2024
  • Table 2-10: Global Gene Therapy Pipeline, by Phase, Q4 ’22-Q1 ’24 (count, %)
  • Figure 2-5: Global Gene Therapy Pipeline Shares by Phase, Q1 ’24 (%)

Pipeline by Condition and Therapeutic Area

  • Table 2-11: Global Cell, Gene, & RNA Therapy Pipeline, by Therapeutic Area (Alimentary/Metabolic, Anticancer, Anti-infective, Blood and Clotting, Cardiovascular, Dermatological, Genitourinary [including sex hormones], Hormonal [excluding sex hormones], Immunological, Musculoskeletal, Neurological, Rare Diseases, Respiratory, Sensory, Miscellaneous, Other), Q4 ’22-Q1 ’24 (count, %)
  • Figure 2-6: Global Gene Therapy Pipeline Shares, by Therapeutic Area (Alimentary/Metabolic, Anticancer, Anti-infective, Blood and Clotting, Cardiovascular, Dermatological, Genitourinary [including sex hormones], Hormonal [excluding sex hormones], Immunological, Musculoskeletal, Neurological, Rare Diseases, Respiratory, Sensory, Miscellaneous), Q1 ’24 (%)
  • Table 2-12: Global Cell, Gene, & RNA Therapy Pipeline Excluding Pre-clinical, by Therapeutic Area (Alimentary/Metabolic, Anticancer, Anti-infective, Blood and Clotting, Cardiovascular, Dermatological, Genitourinary [including sex hormones], Hormonal [excluding sex hormones], Immunological, Musculoskeletal, Neurological, Rare Diseases, Respiratory, Sensory, Miscellaneous), Q4 ’22-Q1 ’24 (count, %)
  • Table 2-13: Global Cell, Gene, & RNA Therapy Pipeline Excluding Pre-clinical, by Rare Disease (Amyotrophic lateral sclerosis; Cancer, gastrointestinal, stomach; Cancer, leukemia, acute myelogenous; Cancer, leukemia, chronic lymphocytic; Cancer, liver; Cancer, lymphoma, B-cell; Cancer, lymphoma, B-cell, diffuse large; Cancer, lymphoma, non-Hodgkin’s; Cancer, lymphoma, T-cell; Cancer, mesothelioma; Cancer, myeloma; Cancer, ovarian; Cancer, pancreatic; Cancer, renal; Cystic fibrosis; Dystrophy, Duchenne’s muscular; Hemophilia A; Hemophilia B; Retinitis pigmentosa; Other), Q4 ’22-Q1 ’24 (count, %)
  • Figure 2-7: Global Cell, Gene, & RNA Therapy Pipeline Excluding Pre-clinical, by Rare Disease (Amyotrophic lateral sclerosis; Cancer, gastrointestinal, stomach; Cancer, leukemia, acute myelogenous; Cancer, leukemia, chronic lymphocytic; Cancer, liver; Cancer, lymphoma, B-cell; Cancer, lymphoma, B-cell, diffuse large; Cancer, lymphoma, non-Hodgkin’s; Cancer, lymphoma, T-cell; Cancer, mesothelioma; Cancer, myeloma; Cancer, ovarian; Cancer, pancreatic; Cancer, renal; Cystic fibrosis; Dystrophy, Duchenne’s muscular; Hemophilia A; Hemophilia B; Retinitis pigmentosa), Q4 ’22-Q1 ’24 (%)
  • Table 2-14: Global Non-GM Cell Therapy Pipeline, by Therapeutic Area (Alimentary/Metabolic, Anticancer, Anti-infective, Blood and Clotting, Cardiovascular, Dermatological, Genitourinary  [including sex hormones], Hormonal [excluding sex hormones], Immunological, Musculoskeletal, Neurological, Rare Diseases, Respiratory, Sensory, Miscellaneous), Q4 ’22-Q1 ’24 (count, %)
  • Table 2-15: Global Non-GM Cell Therapy Pipeline, by Condition/Disease (Alzheimer’s disease; Arthritis, osteo; Cancer, brain; Cancer, breast; Cancer, leukemia, acute myelogenous; Cancer, liver; Cancer, lung, non-small cell; Cancer, melanoma; Cancer, ovarian; Cancer, solid, unspecified; Cancer, unspecified; COVID-19 complications; Diabetes, Type 1; Graft-versus-host disease; Heart failure; Hepatic dysfunction, unspecified; Infarction, myocardial; Ischemia, cerebral; Parkinson’s disease; Respiratory distress syndrome, acute; Spinal cord injury), Q4 ’22-Q1 ’24 (count, %)
  • Table 2-16: Global Non-GM Cell Therapy Pipeline, by Rare Disease Targeted (Amyotrophic lateral sclerosis; Anal fistula; Cancer, gastrointestinal, stomach; Cancer, leukemia, acute myelogenous; Cancer, liver; Cancer, lymphoma, non-Hodgkin’s; Cancer, myeloma; Cancer, ovarian; Cancer, pancreatic; Cancer, renal; Dystrophy, Duchenne’s muscular; Epidermolysis bullosa; Fibrosis, pulmonary, idiopathic; Graft-versus-host disease; Huntington’s disease; Myelodysplastic syndrome; Respiratory distress syndrome, acute; Retinitis pigmentosa; Spinal cord injury; Thalassemia), Q4 ’22-Q1 ’24 (count, %)
  • Table 2-17: Global RNA Therapy Pipeline, by Therapeutic Area (Alimentary/Metabolic, Anticancer, Anti-infective, Antiparasitic, Blood and Clotting, Cardiovascular, Dermatological, Genitourinary  [including sex hormones], Hormonal [excluding sex hormones], Immunological, Musculoskeletal, Neurological, Rare Diseases, Respiratory, Sensory, Miscellaneous), Q4 ’22-Q1 ’24 (count, %)
  • Table 2-18: Global RNA Therapy Pipeline, by Rare Disease Targeted (Amyotrophic lateral sclerosis; Cancer, liver; Cancer, ovarian; Cancer, pancreatic; Cystic fibrosis; Dementia, frontotemporal;  Dystrophy, Duchenne’s muscular; Dystrophy, myotonic muscular; Fibrosis, pulmonary, idiopathic; Huntington’s disease; Infection, malaria prophylaxis; Infection, rabies prophylaxis; Primary ciliary dyskinesia; Respiratory distress syndrome, acute), Q4 ’22-Q1 ’24 (count, %)

Phase III Development

  • Table 2-19: Phase III Development – Cell and Gene Therapies, Select Projects

End Users

Hospitals

Research Institutes

Wound Care Centers

Cancer Centers

 

Chapter 3: Cell and Gene Therapy Markets in Oncology

Overview

Biochemistry of Cancer Cells

Causes of Cancer Growth

Environmental Factors, DNA, RNA

  • Table 3-1: Virus Association with Human Cancer

Cellular Oncogenes

Tumor Suppressor Genes

Global Cancer Burden

  • Figure 3-1: Estimated Number of New Cancer Cases from 2020 to 2040, Both Sexes, Age 0-85+, All Cancers
  • Figure 3-2: Incidence of Cancer, by Type (Bladder, Breast, Cervix Uteri, Colorectum, Liver, Lung, Oesophagus, Prostate, Stomach, Thyroid), 2020
  • Figure 3-3: Worldwide Distribution of Cancer Incidence, by Type (Brest, Cervix Uteri, Colorectum, Liver, Lung, Prostate, Stomach, Other Cancers), 2020

Market Outlook

  • Table 3-2: Cell, Gene, & RNA Therapy Markets in Oncology, 2023-2029 ($ millions)
  • Figure 3-4: Cell, Gene, & RNA Therapy Markets in Oncology, 2023-2029 ($ millions)

Principal Products

Abecma

APCeden

Breyanzi

Carvykti

CreaVax-RCC

Delytact

Gendicine

Imlygic

Immuncell-LC

Kymriah

Provenge

Tecartus

Yescarta

  • Table 3-3: Cell and Gene Therapy in Oncology

Trends in Research and Development

Phase III Development

  • Table 3-4: Select Oncology Phase III Cell, Gene, & RNA Therapy Developments, through March 2024

Market Breakdown of Cell and Gene Therapies

  • Table 3-5: Oncology Cell and Gene Therapy Markets, by Product Type (CAR-T, Cell Immunotherapy, Gene Therapy), Estimated 2023 and Projected 2029 ($ millions)
  • Figure 3-5: Oncology Cell and Gene Therapy Market Distribution, by Product Type (CAR-T, Cell Immunotherapy, Gene Therapy), 2023 (%)

Oncology Cell and Gene Therapy Market by Cancer Type

  • Table 3-6: Oncology Cell, Gene, & RNA Therapy Market, by Cancer Type (Leukemia, Lymphoma, Melanoma, Multiple Myeloma, Prostate Cancer,  Undefined Blood Cancer, Other Cancers), Estimated 2023 and Projected 2029 ($ millions)
  • Table 3-7: Oncology Cell, Gene, & RNA Therapy Market, by General Indication (Leukemia, Lymphoma, Melanoma, Multiple Myeloma, Prostate Cancer, Other Cancers), 2023 (%)
  • Figure 3-6: Oncology Cell, Gene, & RNA Therapy Market, by General Indication (Leukemia, Lymphoma, Melanoma, Multiple Myeloma, Prostate Cancer, Other Cancers), 2023 (%)

Regional Market Summary

  • Table 3-8: Oncology Cell and Gene Therapy Market, by Country/Region (Europe, United States, Other Countries), Estimated 2023 and Projected 2029 ($ millions)
  • Figure 3-7: Oncology Cell and Gene Therapy Market Summary, by Geographic Region (Europe, United States, Other Countries), Estimated 2023 and Projected 2029 ($ millions)

Competitor Summary

  • Table 3-9: Oncology Cell, Gene, & RNA Therapy Competitor Market Share, Reported and Estimated 2023 ($ millions)
  • Figure: 3-8: Oncology Cell, Gene, & RNA Therapy Competitor Market Share, Estimated 2023 (%)

 

Chapter 4: Cell and Gene Therapy Markets in Neurological-Related Disorders

Overview

Market Outlook

  • Table 4-1: Cell, Gene, and RNA Therapies in Neurological-Related Conditions, 2023-2029 ($ millions)
  • Figure 4-1: Cell, Gene, and RNA Therapies in Neurological-Related Conditions, 2023-2029 ($ millions)

Principal Products

Amvuttra

Libmeldy/ Lenmeldy

NeuroNata-R

Onpattro

SKYSONA

Spinraza

Stemirac

Wainua

Zolgensma

  • Table 4-2: Cell, Gene, and RNA Therapy in Neurological Diseases and Disorders

Trends in Research and Development

Phase III Development

  • Table 4-3: Select Neurological Phase III Cell and Gene Therapy Developments, through March 2024

Market Breakdown of Cell and Gene Therapies

  • Table 4-4: Neurological Conditions Cell and Gene Therapy Markets, by Product Type (Cell Therapy, Gene Therapy, RNA/Antisense Therapy), Estimated 2023 and Projected 2029 ($ millions)
  • Figure 4-2: Neurological Conditions Cell, Gene, & RNA Therapy Market Distribution, by Product Type, 2023 (%)

Regional Market Summary

  • Table 4-5: Neurological Conditions Cell and Gene Therapy Market, by Country/Region (Europe, United States, Other Countries), Estimated 2023 and Projected 2029 ($ millions)
  • Figure 4-3: Neurological Conditions Cell, Gene, & RNA Therapy Market Summary, by Geographic Region (Europe, United States, Other Countries), Estimated 2023 and Projected 2029 ($ millions)

Competitor Summary

  • Table 4-6: Neurological Conditions Cell and Gene Therapy Competitor Market Share, Reported and Estimated 2023 ($ millions)
  • Figure 4-4: Neurological Conditions Cell, Gene, & RNA Therapy Market Shares, by Company, Estimated 2023 ($ millions)

 

Chapter 5: Cell and Gene Therapy Markets in Musculoskeletal Conditions and Disorders

Overview

Market Outlook

  • Table 5-1: Cell, Gene, & RNA Therapy Markets in Musculoskeletal Conditions and Disorders, 2023-2029 ($ millions)
  • Figure 5-1: Cell, Gene, & RNA Therapy Markets in Musculoskeletal Conditions and Disorders, 2023-2029 ($ millions)

Principal Products

AlloStem

Amondys

BIO4

Carticel

Cartiform

CartiLife

Cartistem

Chondron

Elevidys

Exondys

JACC

MACI

Ortho-ACI and Ortho-ATI

Ossron

Osteocel and Osteoplus

Spherox

Trinity Elite and Trinity Evolution

Vyondys

  • Table 5-2: Cell and Gene Therapies in Musculoskeletal Diseases and Disorders

Trends in Research and Development

Phase III Development

  • Table 5-3: Select Musculoskeletal Phase III Cell and Gene Therapy Developments, through March 2024

Market Breakdown of Cell and Gene Therapies

  • Table 5-4: Musculoskeletal Cell, Gene, & RNA Therapy Markets, by Product Type, Estimated 2023 and Projected 2029 ($ millions)

Musculoskeletal Cell and Gene Therapy Market by Indication

  • Table 5-5: Musculoskeletal Cell, Gene, & RNA Therapy Market, by General Indication (Bone Defect/Damage Repair, Cartilage Defect/Damage Repair, DMD, Others [Tendon Damage, Osteoarthritis]), Estimated 2023 and Projected 2029 ($ millions)
  • Figure 5-2: Musculoskeletal Cell, Gene, & RNA Therapy Market, by General Indication (Bone Defect/Damage Repair, Cartilage Defect/Damage Repair, DMD, Others [Tendon Damage, Osteoarthritis]), Estimated 2023 (%)

Regional Market Summary

  • Figure 5-3: Musculoskeletal Cell, Gene, & RNA Therapy Market, by Country/Region (Europe, United States, South Korea, ROW), Estimated 2023 (%)
  • Table 5-6: Musculoskeletal Cell, Gene, & RNA Therapy Market, by Country/Region (Europe, United States, South Korea, ROW), Estimated 2023 and Projected 2029 ($ millions)
  • Figure: 5-4: Musculoskeletal Cell and Gene Therapy Market Summary, by Geographic Region (Europe, United States, South Korea, ROW), Estimated 2023 and Projected 2029 ($ millions)

Competitor Summary

  • Table 5-7: Musculoskeletal Cell, Gene, & RNA Therapy Competitor Market Share, Reported and Estimated 2023 ($ millions)
  • Figure 5-5: Musculoskeletal Cell, Gene, & RNA Therapy Market Shares, by Company, Estimated 2023 (%)

 

Chapter 6: Cell and Gene Therapy Markets in Dermatology

Overview

  • Table 6-1: Wound Prevalence, by Type (Skin Ulcers: Pressure Injuries, Venous Statis Ulcers, Diabetic Ulcers and Burns: Outpatient Burns, Hospitalized Burns, and Medically Treated Burns)

Market Outlook

  • Figure 6-1: Cell and Gene Therapy Markets in Dermatology, 2023-2029 ($ millions)

Principal Products

Adipocel

Apligraf

CureSkin

Dermagraft

Epicel

Grafix

Holoderm

Kaloderm

KeraHeal/KeraHeal-Allo

LaViv

Orcel

Quencell

RECELL

Rosmir

Stempeutics/Cutisera

StrataGraft

Stravix

TransCyte

Vyjuvek

  • Table 6-2: Cell and Gene Therapy in Dermatological Diseases and Disorders

Trends in Research and Development

Phase III Development

  • Table 6-3: Select Dermatology Phase III Cell and Gene Therapy Developments, through March 2024

Market Breakdown of Cell and Gene Therapies

  • Table 6-4: Dermatology Cell and Gene Therapy Markets, by Product Type (Stem Cells, Skin Cells, Gene/Gene-Modified Cell Therapy), Estimated 2023 and Projected 2029 ($ millions)
  • Figure 6-2: Dermatology Cell and Gene Therapy Market Distribution, by Product Type (Stem Cells, Skin Cells, Gene/Gene-Modified Cell Therapy), 2023 (%)

Dermatology Cell and Gene Therapy Market by Indication

Regional Market Summary

  • Table 6-5: Dermatology Cell and Gene Therapy Market, by Country/Region (Asia, Europe, United States, Other Countries), Estimated 2023, Projected 2029 ($ millions)
  • Figure: 6-3: Dermatology Cell and Gene Therapy Market Summary, by Geographic Region (Asia, Europe, United States, ROW), Estimated 2023 and Projected 2029 ($ millions)

Competitor Summary

  • Table 6-6: Dermatology Cell and Gene Therapy Competitor Market Share, Reported and Estimated 2023 ($ millions)
  • Figure: 6-4: Dermatology Cell and Gene Therapy Market Share, by Company, Estimated 2023 (%)

 

Chapter 7: Cell and Gene Therapy Markets in Cardiovascular and Blood Disorders

Overview

Cardiovascular Disease

Selected Blood Disorders

Market Outlook

  • Table 7-1: Cell, Gene, and RNA Therapy Markets in Cardiovascular and Blood Disorders, 2023-2029 ($ millions)
  • Figure 7-1: Cell, Gene, and RNA Therapy Markets in Cardiovascular and Blood Disorders, 2023-2029 ($ millions)

Principal Products

Collategene

Hearticellgram

HeartSheet

Leqvio

Neovasculgen

Stempeucel

Zynteglo

  • Table 7-2: Selected Cell and Gene Therapy in Cardiovascular and Blood Disorders

Phase III Development

  • Table 7-3: Select Cardiovascular and Blood Disorder Phase III Cell and Gene Therapy Developments, through Mar 2023

Market Breakdown of Cell, Gene, and RNA Therapies

  • Table 7-4: Cardiovascular and Blood Disorders Cell, Gene, & RNA Therapy Markets, by Product Type (Cell-based Gene Therapy, Non-GM Cell, RNA, Other Gene Therapies), Estimated 2023 and Projected 2029 ($ millions)
  • Figure 7-2: Cardiovascular and Blood Disorders Cell and Gene Therapy Market Distribution, by Product Type (Cell-based Gene Therapy, Non-GM Cell, RNA, Other Gene Therapies), 2023 (%)

Cardiovascular and Blood Disorders Cell and Gene Therapy Market by Indication

  • Table 7-5: Cardiovascular and Blood Disorders Cell and Gene Therapy Market, by General Indication (Blood, Cardiac, Hypercholesterolemia, Vascular), Estimated 2023 and Projected 2029 ($ millions)

Regional Market Summary

  • Table 7-6: Cardiovascular and Blood Disorders Cell and Gene Therapy Market, by Country/Region (APAC, Europe, United States, ROW), Estimated 2023 and Projected 2029 ($ millions)
  • Figure 7-3: Cardiovascular and Blood Disorders Cell and Gene Therapy Market Summary, by Geographic Region (APAC, Europe, United States, ROW), Estimated 2023 and Projected 2029 ($ millions)

Competitor Summary

 

Chapter 8: Cell and Gene Therapy Markets in Other Conditions

Overview

Market Outlook

  • Figure 8-1: Cell and Gene Therapy Markets in Other Conditions, 2023-2029 ($ millions)
  • Table 8-1: Cell and Gene Therapy Markets in Other Conditions, 2023-2029 ($ millions)

Principal Products

Alofisel

Cupistem

Givlaari

Glybera

Holoclar

Luxturna

Oxlumo

Rethymic

Strimvelis

Temcell/Prochymal/Ryoncil

  • Table 8-2: Cell and Gene Therapy in Other Diseases and Disorders

Trends in Research and Development

Market Breakdown of Cell and Gene Therapies

  • Table 8-3: Other Conditions Cell and Gene Therapy Markets, by Product Type (Cell-based Gene Therapy; RNA, Antisense Etc; Stem Cell & Other Cell Therapy; Other Gene Therapy), Estimated 2023 and Projected 2029 ($ millions)
  • Figure 8-2: Other Conditions Cell and Gene Therapy Market Distribution, by Product Type (Cell-based Gene Therapy; RNA, Antisense Etc; Stem Cell & Other Cell Therapy; Other Gene Therapy), 2023 (%)

Regional Market Summary

  • Table 8-4: Other Conditions Cell and Gene Therapy Market, by Country/Region (Europe, Japan, South Korea, United States, Other Countries), Estimated 2023 and Projected 2029 ($ millions)
  • Figure 8-3: Other Conditions Cell and Gene Therapy Market Summary, by Geographic Region (Europe, Japan, South Korea, United States, Other Countries), Estimated 2023 and Projected 2029 ($ millions)

Competitor Summary

 

Chapter 9: Cell and Gene Therapy Market Review

Market Influences

Global Demographics

  • Table 9-1: Global Population, through 2050 (population in millions)
  • Aging Population
  • Figure 9-1: Global Population Trends, Total Population vs. Age 65+ Population, 2000-2050

Cost Containment

  • Table 9-2: Cost Comparisons for Selected Commercialized Cell and Gene Therapies

Cell and Gene Therapy and Viral Vector Shortages

Global Market Summary

  • Table 9-3: Cell, Gene, and RNA Therapy Market Summary, by Product Segment (Cardio/Non-Oncology Blood, Dermatology, Musculoskeletal, Neurology, Oncology, Other), 2023-2029 ($ millions)
  • Figure 9-2: Cell, Gene, and RNA Therapy Market Summary, by Product Segment (Cardio/Non-Oncology Blood, Dermatology, Musculoskeletal, Neurology, Oncology, Other), 2023-2029 ($ millions)
  • Figure 9-3: Cell and Gene Therapy Market, Distribution of Sales, by Product Segment (Cardio/Non-Oncology Blood, Dermatology, Musculoskeletal, Neurology, Oncology, Other), 2023

Cell vs. Gene Therapy Markets

  • Table 9-4: Cell, Gene, & RNA Therapy Market Summary, by Method (Gene/CBG Therapy, RNA Therapy, Non-GM Cell Therapy), 2023-2029 ($ millions)
  • Figure 9-4: Cell, Gene, & RNA Therapy Market, Distribution of Sales, by Method (Gene/CBG Therapy, RNA Therapy, Non-GM Cell Therapy), 2023 (%)

Regional Market Overview

  • Table 9-5: Cell, Gene, & RNA Therapy Market Summary, by Geographical Region (Europe, United States, Other Countries), 2023-2029 ($ millions)

United States

  • Table 9-6: Cell, Gene, & RNA Therapy Market Summary for United States, by Product Segment (Cardio / Non-Oncology Blood, Dermatology, Musculoskeletal, Neurology, Oncology, Other), 2023-2029 ($ millions)
  • Figure 9-5: U.S. Cell and Gene Therapy Market, Distribution, by Product Segment (Cardio / Non-Oncology Blood, Dermatology, Musculoskeletal, Neurology, Oncology, Other), 2023 (%)
  • Table 9-7: Major Cell and Gene Therapy Product Approvals, FDA

Europe/European Union

  • Table 9-8: Cell, Gene, & RNA Therapy Market Summary for Europe/European Union, by Product Segment (Cardio / Non-Oncology Blood, Dermatology, Musculoskeletal, Neurology, Oncology, Other), 2023-2029 ($ millions)
  • Figure 9-6: Europe Cell and Gene Therapy Market Distribution, by Product Segment (Cardio / Non-Oncology Blood, Dermatology, Musculoskeletal, Neurology, Oncology, Other), 2023 (%)
  • Table 9-9: Major Cell and Gene Therapy Approvals by EMA

Other Countries

  • Table 9-10: Cell, Gene, & RNA Therapy Market Summary for Other Countries, by Product Segment (Cardio / Non-Oncology Blood, Dermatology, Musculoskeletal, Neurology, Oncology, Other), 2023-2029  ($ millions)
  • Figure 9-7: ROW Cell, Gene, & RNA Therapy Market Distribution, by Product Segment (Cardio / Non-Oncology Blood, Dermatology, Musculoskeletal, Neurology, Oncology, Other), 2023 (%)
  • Table 9-11: Select Major Cell and Gene Therapy Approvals by Various Regulatory Authorities

Competitor Ranking in Cell and Gene Therapy Markets

  • Table 9-12: Estimated Cell and Gene Therapy Sales by Leading Competitor, 2023 Sales ($ millions)
  • Figure 9-8: Cell and Gene Therapy Market Share Estimates, 2023

 

Chapter 10: Market Participants

Leading Influencers

AlloSource

  • Table 10-1: AlloSource Corporate Summary

Company Summary

Products

Alnylam Pharmaceuticals, Inc.

  • Table 10-2: Alnylam Pharmaceuticals Corporate Summary

Company Summary

Products

Amgen

  • Table 10-3: Amgen Corporate Summary

Company Summary

Products

AnGes Inc.

  • Table 10-4: AnGes Corporate Summary

Company Summary

Products

Anterogen Co Ltd.

  • Table 10-5: Anterogen Corporate Summary

Company Summary

Products

Atara Biotherapeutics

  • Table 10-6: Atara Biotherapeutics Corporate Summary

Company Summary

Products

Athersys, Inc

  • Table 10-7: Athersys Corporate Summary

Company Summary

Products

BioCardia

  • Table 10-8: BioCardia Summary

Company Summary

Products

Biogen, Inc.

  • Table 10-9: Biogen Corporate Summary

Company Summary

Products

BioMarin Pharmaceuticals

  • Table 10-10: BioMarin Pharmaceuticals Corporate Summary

Company Summary

Products

bluebird bio, Inc.

  • Table 10-11: bluebird bio Corporate Summary

Company Summary

Products

BrainStorm Cell Therapeutics

  • Table 10-12: BrainStorm Cell Therapeutics Corporate Summary

Company Summary

Products

Bristol-Myers Squibb

  • Table 10-13: Bristol-Myers Squibb Corporate Summary

Company Summary

Products

Candel Therapeutics

  • Table 10-14: Candel Therapeutics Corporate Summary

Company Summary

Products

Castle Creek Biosciences

  • Table 10-15: Castle Creek Corporate Summary

Company Summary

Products

Celyad Oncology

  • Table 10-16: Celyad Oncology Corporate Summary

Company Summary

Products

Cook Myosite, Inc

  • Table 10-17: Cook Myosite Corporate Summary

Company Summary

Products

Dendreon Pharmaceuticals (Sanpower)

  • Table 10-18: Dendreon Corporate Summary

Company Summary

Products

FerGene, Inc (Ferring Pharmaceuticals)

  • Table 10-19: FerGene Corporate Summary

Company Summary

Products

Gamida Cell Ltd.

  • Table 10-20: Gamida Cell Corporate Summary

Company Summary

Products

GenSight Biologics S.A.

  • Table 10-21: GenSight Biologics Corporate Summary

Company Summary

Products

Gilead Sciences, Inc.

  • Table 10-22: Gilead Sciences Corporate Summary

Company Summary

Products

Gradalis, Inc

  • Table 10-23: Gradalis Corporate Summary

Company Summary

Products

Helixmith

  • Table 10-24: Helixmith Corporate Summary

Company Summary

Products

Inovio Pharmaceuticals, Inc.

  • Table 10-25: Inovio Pharmaceuticals Corporate Summary

Company Summary

Products

Kiadis Pharma B.V. (Sanofi)

  • Table 10-26: Kiadis Pharma Corporate Summary

Company Summary

Products

Medeor Therapeutics

  • Table 10-27: Medeor Therapeutics Corporate Summary

Company Summary

Products

MEDIPOST Co, Ltd.

  • Table 10-28: MEDIPOST Corporate Summary

Company Summary

Products

MeiraGTx

  • Table 10-29: MeiraGTxCorporate Summary

Company Summary

Products

Mesoblast Ltd.

  • Table 10-30: Mesoblast Corporate Summary

Company Summary

Products

Northwest Biotherapeutics, Inc.

  • Table 10-31: Northwest Biotherapeutics Corporate Summary

Company Summary

Products

Novartis AG

  • Table 10-32: Novartis Corporate Summary

Company Summary

Products

NuVasive Biologics

  • Table 10-33: NuVasive Biologics Corporate Summary

Company Summary

Products

Orchard Therapeutics

  • Table 10-34: Orchard Therapeutics Corporate Summary

Company Summary

Products

Organogenesis

  • Table 10-35: Organogenesis Corporate Summary

Company Summary

Products

Orthofix

  • Table 10-36: Orthofix Corporate Summary

Company Summary

Products

Osiris Therapeutics, Inc. (part of Smith & Nephew)

  • Table 10-37: Osiris Corporate Summary

Company Summary

Products

Pharmicell

  • Table 10-38: Pharmicell Corporate Summary

Company Summary

Products

Pluristem Therapeutics, Inc.

  • Table 10-39: Pluristem Therapeutics Corporate Summary

Company Summary

Products

Sangamo Therapeutics

  • Table 10-40: Sangamo Therapeutics Corporate Summary

Company Summary

Products

Sanofi

  • Table 10-41: Sanofi Corporate Summary

Company Summary

Products

Sarepta

  • Table 10-42: Sarepta Corporate Summary

Company Summary

Products

Sotio a.s.

  • Table 10-43: Sotio Corporate Summary

Company Summary

Products

Spark Therapeutics

  • Table 10-44: Spark Therapeutics Corporate Summary

Company Summary

Products

Tessa Therapeutics, Ltd.

  • Table 10-45: Tessa Therapeutics Corporate Summary

Company Summary

Products

uniQure N.V.

  • Table 10-46: UniQure Corporate Summary

Company Summary

Products

Vericel Corporation

  • Table 10-47: Vericel Corporate Summary

Company Summary

Products

 

Our Knowledge Center provides access to

all market reports